BMJ1d
2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease by Wallace et al
Correspondence to Professor Sang-Won Lee, Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Korea (the Republic of); SANGWONLEE{at}yuhs.ac The mean age of the patients was 60.2 ...
BMJ2d
Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica
Correspondence to Dr. Kornelis S M van der Geest, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, 9712 CP Groningen, Netherlands; ...
BMJ7d
Axial spondyloarthritis
Axial spondyloarthritis (axSpA) encompasses both radiographic and non-radiographic axSpA. It is a chronic inflammatory disease with a predilection for involving the axial skeleton. The most common ...
BMJ5d
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
Objectives Risankizumab is an interleukin-23 inhibitor under study for the treatment of patients with psoriatic arthritis (PsA). The phase 3 KEEPsAKE 2 trial investigated the efficacy and safety of ...
BMJ12d
Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis
Objectives The study (206347) compared organ damage progression in patients with systemic lupus erythematosus (SLE) who received belimumab in the BLISS long-term extension (LTE) study with propensity ...
BMJ11d
Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial
Correspondence to Professor Margreet Kloppenburg, Department of Rheumatology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands; g.kloppenburg{at}lumc.nl Objective Hand osteoarthritis ...
BMJ8d
Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals
Objective Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with unknown aetiology. Epstein-Barr virus (EBV) is an environmental factor associated with SLE. EBV maintains latency in ...
BMJ4d
Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis
Objective To compare the effects of interleukin-6 (IL-6) receptor and tumour necrosis factor inhibition on inducing repair of existing bone erosions in patients with very early rheumatoid arthritis ...
BMJ7d
Novel and reliable DACTylitis glObal Sonographic (DACTOS) score in psoriatic arthritis
Correspondence to Professor Annamaria Iagnocco, Scienze Cliniche e Biologiche, Università degli Studi di Torino, Turin 10043, Italy; annamaria.iagnocco1{at}gmail.com Objectives Dactylitis is one of ...
BMJ8d
First metatarsophalangeal joint aspiration using a 29-gauge needle
Objectives: To asses the clinical feasibility of aspirating symptomatic and asymptomatic first metatarsophalangeal (MTP) joints with a 29-gauge needle in order to obtain a synovial fluid (SF) sample.
BMJ10d
Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis
Dr P van Lent, Department of Rheumatology, UMC Nijmegen, Building 850, Geert Grooteplein 26–28, Nijmegen, The Netherlands; P.vanlent{at}reuma.umcn.nl Objective: To study the active involvement of ...
BMJ1d
AB1524 EXPLORING THE SAFETY AND EFFECTIVENESS OF BIOSIMILARS BIOLOGICAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS DURING PREGNANCY
Background: Biosimilar biological disease modifying anti-rheumatic drugs (B-bDMARDs) are a cost-effective treatment for autoimmune rheumatic diseases (ARDs). Despite current guidelines [3] consider ...